Chargement en cours...
Conversion from cilostazol to OPC‐13015 linked to mitigation of cognitive impairment
INTRODUCTION: Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than cilostazol. METHODS: We prospectively enrolled patients with mild cognitive impairment to whom cilostazol was newly pre...
Enregistré dans:
| Publié dans: | Alzheimers Dement (N Y) |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8158162/ https://ncbi.nlm.nih.gov/pubmed/34095441 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/trc2.12182 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|